Join
Live feed
·
PRReleasevia Quantisnow
ProMIS Neurosciences Inc. logo

ProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzheimer’s Disease

ByQuantisnow·Wall Street's wire, on your screen.
PMN· ProMIS Neurosciences Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track PMN (ProMIS Neurosciences Inc.) and more on Quantisnow.